RE:RE:RE:Gilles destroyer of shareholders "Does anyone believe AEZS could issue more shares to raise funds for their pipeline given their track record?"
It's night and Ciao thinks it will always be dark. The sun comes out in the morning and he's wrong again. We've been in the worst biotech market on record. Many preclinical assets have been trading below cash. That's the potential opportunity as bull markets follow bear markets. The sun can come out again in biotech. CZO has picked off AEZS's assets potentially at the bottom of the biotech market.
CZO's news release:
"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business, which is optimally positioned to deliver value as the biopharma sector recovers from its current levels."
----------
Worst Biotech Bear Market On Record The Sub 200M market cap bracket has seen the largest decline since 2/8/21, with an average drop of -86% and a median of -93%. Companies in the 200M-500M range lost over half their value since the peak, with a median decline of -79%. Larger companies, specifically those with a market cap of 8B+, showed resilience with an average return of 11% year-to-date and an increase of 9% since the 2/8/21 peak. Across all market cap buckets, there's been an average decline of -43% since 2/8/21, with a median drop of -54%. The number of companies with a negative enterprise value (EV) surged from 6 on 2/8/21 to 221 (35%) currently. Remarkably, 71% of these negative EV companies have l